Susan Piascik Christoff

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised Blue Owl Capital (NYSE: OWL), a top asset manager that is redefining alternatives, and HealthCare Royalty (HCRx), a top royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, on a $250 million term loan facility with TG Therapeutics (NASDAQ: TGTX), a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.

Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million.